Galderma stock: Citi sets CHF 185.00 target for Galderma stock

Published on 10/19/2026 at 15:39 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The next Galderma report is scheduled for March 11, 2027. Galderma stock costs EUR 188.50 on October 19, 2026 at 3:32 p.m. CEST at Lang & Schwarz.

Target and valuation frame

Citi initiated coverage with a CHF 185.00 target on October 16, 2026.
The next Galderma report is scheduled for March 11, 2027.
Galderma stock costs EUR 188.50 at 3:32 p.m. CEST at Lang & Schwarz on October 19, 2026.
Galderma's market capitalization is CHF 40.7 billion and its P/E ratio is 58.15.

Galderma, CH1335392721, Illustration mit AI erstellt.

Galderma Group stock has a fresh CHF 185.00 price target from Citi, which began coverage on October 16, 2026. The target stands 6.08 percent above the SIX price of CHF 174.40 from the same session. At Lang & Schwarz, the stock was trading at EUR 188.50 on October 19, 2026 at 3:32 p.m. CEST.

Citi puts CHF 185.00 in view

According to Markets Insider on October 16, 2026, Citi analyst Cedric Besnard initiated coverage with a Buy rating and set the CHF 185.00 target. The same report said Barclays maintained a Buy rating with a CHF 220.00 target on September 30, 2026, but the newer Citi view is closer to the current SIX quotation.

Range leaves little room above

Galderma traded between CHF 134.90 and CHF 188.25 over the past 52 weeks, according to the latest market snapshot dated October 19, 2026. The CHF 174.40 SIX price was 7.37 percent below the yearly high, while the Lang & Schwarz euro quote was EUR 188.50 at 3:32 p.m. CEST. The SIX quote was down 0.94 percent from CHF 176.05 at 3:21 p.m. CEST.

Valuation and next reporting date

The company's market capitalization was CHF 40.7 billion, with a P/E ratio of 58.15 and a trading volume of 137,121 shares on October 19, 2026. TradingView lists March 11, 2027 as the next report date for the second half of 2026. Galderma trades on SIX and belongs to the Swiss Market Index, a status the company announced on September 21, 2026 in an official release.

Comparison with peers

Galderma (SIX, CHF): minus 0.94 percent, P/E 58.15, market capitalization CHF 40.7 billion
Pfizer (NYSE, USD): plus 0.20 percent, P/E 39.16, market capitalization USD 168.9 billion
EssilorLuxottica (Euronext Paris, EUR): minus 3.11 percent, P/E 27.93, market capitalization EUR 68.8 billion

Price and market position

The current euro quotation places Galderma close to its 52-week high in the Swiss listing, while the latest analyst target remains below that high in absolute terms. The next scheduled reporting date gives investors a defined calendar point for reassessing the valuation.

At Lang & Schwarz, Galderma was trading at EUR 188.50 on October 19, 2026 at 3:32 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Galderma stock.